Digital Dose Inhaler Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Digital Dose Inhaler Market is Segmented by Product (Dry Powder Inhalers and Metered Dose Inhalers), Application, Type, and Geography.

Market Snapshot

Digital Dose Inhaler Market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 13.3 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The digital dose inhaler market is anticipated to grow with a CAGR of above 13.3% during the forecast period. The major factors attributing to the growth of the digital dose inhaler market include the rising prevalence of chronic respiratory diseases and the growing demand for technology-enabled features of the respiratory devices.

Soaring geriatric populations suffering from respiratory disorders and favorable reimbursement policies also play a significant role in the growth of the market. According to the report of the Global Asthma Network 2018, around 339 million people are affected by Asthma, and the prevalence is rising. The rising prevalence of respiratory diseases globally is pushing the market growth. However, the high cost of the inhalers is the constraint to the growth of the market.

Scope of the Report

According to the scope of the report, digital dose inhalers are devices that deliver a specific amount of medication to the lungs in the form of aerosolized medicine or dry powder.

By Product
Dry Powder Inhalers
Metered Dose Inhalers
By Application
Chronic Obstructive Pulmonary Disease
By Type
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Dry Powder Inhalers (DPI) are Expected to Hold a Major Share in the Growth of the Market

Dry powder inhalers are devices that deliver medication to the lungs in the form of a dry powder. The major factors attributing to the growth of the dry powder inhaler segment are the prevalence of chronic respiratory diseases like COPD, Asthma, etc. and growing demand for technology-enabled features of the respiratory devices. Problems related to the occurrences of drug irritation caused by the existence of propellant components, such as chlorofluorocarbons (CFCs) in MDI, have boosted the usage of the DPIs, with lesser irritant impacts while providing therapeutic efficacy as MDIs.Hence the DPIs are called the green inhalers.

Though the MDIs hold a significant market share, the adoption of the manufacturing of DPIs by the health care providers increases production in the coming years.

Digital Dose Inhaler Market

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall digital dose inhaler market throughout the forecast period. The growth is credited to the meticulous research and development programs, increasing awareness regarding the presently available, hi-tech respiratory devices. Also, an increase in the prevalence of respiratory conditions among both the pediatric and the elderly population will further benefit market growth. 

According to the Asthma and Allergy Foundation of America (AAFA), every day, 10 Americans die from asthma, and 3,564 people died from asthma in 2017. With the increasing prevalence of chronic respiratory diseases, the digital dose inhaler market in the region grows proportionally.

Digital Dose Inhaler Market

Competitive Landscape

The digital dose inhaler market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market include Glenmark Pharmaceuticals Ltd., AstraZeneca Plc, Novartis International AG, Propeller Health, Philips Respironics, Opko Health, Inc., and Teva Pharmaceutical Industries Ltd.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Chronic Respiratory Diseases

      2. 4.2.2 Soaring Geriatric Population Afflicted With Respiratory Disorders

      3. 4.2.3 Increasing R&D Investment for Technological Improvement and Device Miniaturization

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of the Devices

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Product

      1. 5.1.1 Dry Powder Inhalers

      2. 5.1.2 Metered Dose Inhalers

    2. 5.2 By Application

      1. 5.2.1 Chronic Obstructive Pulmonary Disease

      2. 5.2.2 Asthma

      3. 5.2.3 Others

    3. 5.3 By Type

      1. 5.3.1 Branded

      2. 5.3.2 Generic

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Glenmark Pharmaceuticals

      2. 6.1.2 Novartis International AG

      3. 6.1.3 AstraZeneca Plc

      4. 6.1.4 Propeller Health

      5. 6.1.5 Koninklijke Philips N.V.

      6. 6.1.6 Opko Health, Inc.

      7. 6.1.7 Teva Pharmaceutical Industries Ltd.

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Digital Dose Inhaler Market market is studied from 2018 - 2026.

The Digital Dose Inhaler Market is growing at a CAGR of 13.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Glenmark Pharmaceuticals, Novartis International AG, AstraZeneca Plc, Propeller Health, Koninklijke Philips N.V. are the major companies operating in Digital Dose Inhaler Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!